Hexaminolevulinate (Cysview®, Hexvix®) for bladder cancer detection
Record ID 32013000172
English
Authors' recommendations:
As bladder cells become cancerous, they undergo numerous molecular changes, including specific alterations in DNA content and new or increased expression of a variety of enzymes, proteins, and antigens. One such change is an increase in the enzymes that participate in formation of fluorescent heme molecules. Hexaminolevulinate hydrochloride (HCL) (Cysview® [Photocure USA]; Hexvix® [Photocure ASA, Norway]) as an imaging agent that stimulates heme formation, which presumably results in increased fluorescence of precancerous and cancerous cells when instilled in the bladder. The purpose of Cysview is to improve detection of bladder cancer during an endoscopic examination of the bladder and during resection of bladder cancer.
Details
Project Status:
Completed
Year Published:
2012
URL for published report:
The report may be purchased from:http://www.hayesinc.com/hayes/crd/?crd=14556
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
MeSH Terms
- Aminolevulinic Acid
Contact
Organisation Name:
HAYES, Inc.
Contact Address:
157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218
Contact Name:
saleinfo@hayesinc.com
Contact Email:
saleinfo@hayesinc.com
Copyright:
2012 Winifred S. Hayes, Inc
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.